Top research highlights from ESMO Breast Cancer 2025 showcase advances in treatment and care for patients with breast cancer. Imlunestrant plus abemaciclib improved PFS across subgroups in ER+/HER2- breast cancer, per EMBER-3 data. Abemaciclib plus fulvestrant showed benefit across biomarkers after CDK4/6i failure in advanced HR+/HER2- breast cancer. About 40% of patients on AI + palbociclib developed ESR1 mutations in PADA-1, emerging as early as 6 months into treatment. Zanidatamab plus chemo showed promising responses in HER2+ and HER2-low mBC, with durable activity in a phase I trial. Dual immunotherapy plus trastuzumab shows activity in ER+ or PD-L1+ trastuzumab-resistant HER2+ breast cancer. T-DXd improved PFS and response rates vs chemo in HR+/HER2-low or -ultralow metastatic breast cancer in DESTINY-Breast06. Emiltatug ledadotin showed early clinical activity and was well tolerated in heavily pretreated patients with TNBC. Ribociclib plus ET shows similar pCR rates to chemo in intermediate-risk HR+/HER2– early breast cancer, per WSG ADAPTcycle. In-depth coverage of the top stories from the ESMO Breast Cancer 2025 Annual Meeting.